These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15958627)

  • 81. Current status of gene therapy for breast cancer: progress and challenges.
    McCrudden CM; McCarthy HO
    Appl Clin Genet; 2014; 7():209-20. PubMed ID: 25419154
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children.
    Shevtsov MA; Kim AV; Samochernych KA; Romanova IV; Margulis BA; Guzhova IV; Yakovenko IV; Ischenko AM; Khachatryan WA
    Onco Targets Ther; 2014; 7():1071-81. PubMed ID: 24971017
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Immune response to sipuleucel-T in prostate cancer.
    Thara E; Dorff TB; Averia-Suboc M; Luther M; Reed ME; Pinski JK; Quinn DI
    Cancers (Basel); 2012 Apr; 4(2):420-41. PubMed ID: 24213318
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Immunocytokines: a review of molecules in clinical development for cancer therapy.
    List T; Neri D
    Clin Pharmacol; 2013; 5(Suppl 1):29-45. PubMed ID: 23990735
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Trial watch: DNA vaccines for cancer therapy.
    Senovilla L; Vacchelli E; Garcia P; Eggermont A; Fridman WH; Galon J; Zitvogel L; Kroemer G; Galluzzi L
    Oncoimmunology; 2013 Apr; 2(4):e23803. PubMed ID: 23734328
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Preexisting antitumor immunity augments the antitumor effects of chemotherapy.
    Zhang L; Feng D; Yu LX; Tsung K; Norton JA
    Cancer Immunol Immunother; 2013 Jun; 62(6):1061-71. PubMed ID: 23595208
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.
    Ramakrishnan R; Huang C; Cho HI; Lloyd M; Johnson J; Ren X; Altiok S; Sullivan D; Weber J; Celis E; Gabrilovich DI
    Cancer Res; 2012 Nov; 72(21):5483-93. PubMed ID: 22942258
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.
    Adams S; Kozhaya L; Martiniuk F; Meng TC; Chiriboga L; Liebes L; Hochman T; Shuman N; Axelrod D; Speyer J; Novik Y; Tiersten A; Goldberg JD; Formenti SC; Bhardwaj N; Unutmaz D; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6748-57. PubMed ID: 22767669
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
    Madan RA; Bilusic M; Heery C; Schlom J; Gulley JL
    Semin Oncol; 2012 Jun; 39(3):296-304. PubMed ID: 22595052
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Therapeutic cancer vaccines: current status and moving forward.
    Schlom J
    J Natl Cancer Inst; 2012 Apr; 104(8):599-613. PubMed ID: 22395641
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Technologies for enhanced efficacy of DNA vaccines.
    Saade F; Petrovsky N
    Expert Rev Vaccines; 2012 Feb; 11(2):189-209. PubMed ID: 22309668
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
    Mohebtash M; Tsang KY; Madan RA; Huen NY; Poole DJ; Jochems C; Jones J; Ferrara T; Heery CR; Arlen PM; Steinberg SM; Pazdur M; Rauckhorst M; Jones EC; Dahut WL; Schlom J; Gulley JL
    Clin Cancer Res; 2011 Nov; 17(22):7164-73. PubMed ID: 22068656
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.
    Hunter TB; Manimala NJ; Luddy KA; Catlin T; Antonia SJ
    Anticancer Res; 2011 Oct; 31(10):3193-204. PubMed ID: 21965726
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Viral vector-based therapeutic cancer vaccines.
    Larocca C; Schlom J
    Cancer J; 2011; 17(5):359-71. PubMed ID: 21952287
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Impact of tumour volume on the potential efficacy of therapeutic vaccines.
    Gulley JL; Madan RA; Schlom J
    Curr Oncol; 2011 Jun; 18(3):e150-7. PubMed ID: 21655153
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impaired tumor antigen processing by immunoproteasome-expressing CD40-activated B cells and dendritic cells.
    Anderson KS; Zeng W; Sasada T; Choi J; Riemer AB; Su M; Drakoulakos D; Kang YJ; Brusic V; Wu C; Reinherz EL
    Cancer Immunol Immunother; 2011 Jun; 60(6):857-67. PubMed ID: 21400024
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The current and emerging role of immunotherapy in prostate cancer.
    Madan RA; Gulley JL
    Clin Genitourin Cancer; 2010 Dec; 8(1):10-6. PubMed ID: 21208850
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
    Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
    Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.
    Ramakrishnan R; Gabrilovich DI
    Cancer Immunol Immunother; 2011 Mar; 60(3):419-23. PubMed ID: 20976448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.